Alle Studien
RekrutierungPHASE1, PHASE2INTERVENTIONELL

A Study of Pirtobrutinib in Participants With Immune Thrombocytopenia

This research study is looking into a new medicine, pirtobrutinib, for adults with Immune Thrombocytopenia (ITP). ITP is a condition where your immune system mistakenly attacks and destroys platelets, which are tiny blood cells that help your blood clot. The study has two main parts. The first part will check how well people tolerate pirtobrutinib and look for any unwanted side effects. The second part will compare different doses of pirtobrutinib against a dummy pill (placebo) to see how effective it is in increasing platelet counts and if it's safe. Taking part involves taking the study medicine by mouth and having regular blood tests.

Auf einen Blick

Status
Rekrutierung
Phase
PHASE1, PHASE2
Sponsor
Eli Lilly und Unternehmen
Einschreibeziel
68
Starten
30. Juli 2025
Geschätzte Fertigstellung
01 Feb 2029

Worum geht es in dieser Studie?

This study is about a new medicine called pirtobrutinib for adults who have a condition called Immune Thrombocytopenia, or ITP. ITP happens when your body's defence system, called the immune system, gets confused and starts attacking your own platelets. Platelets are really important because they help your blood clot and stop bleeding. If you have ITP, your platelet count can be very low, which increases your risk of bruising and bleeding.

The main goal of this study is to find out if pirtobrutinib is a safe and effective treatment for ITP. The study will happen in two stages. First, we need to understand if the medicine is well-tolerated and what kind of side effects it might have. This helps us ensure patient safety. After that, we'll look more closely at whether different amounts (doses) of pirtobrutinib can help increase platelet counts compared to a 'dummy' pill that contains no medicine (a placebo).

If you take part, you'll be given the study medicine, pirtobrutinib, as a tablet to swallow. The researchers will also take blood samples regularly. These blood tests help them understand how much of the medicine gets into your body and how long it stays there. The study will last for different periods depending on which part you are in, but it could be up to about 16 weeks for the first stage or up to 28 weeks for the second stage, not including the initial checks to see if you can join.

Wichtige Erkenntnisse

  • This study is testing a new medicine, pirtobrutinib, for adults with ITP.
  • It aims to check the safety and effectiveness of the medicine.
  • Participants will take the medicine as a tablet and have regular blood tests.
  • The study has two parts: one to find the right dose, and another to compare it with a dummy pill.
  • Taking part means frequent clinic visits and medical supervision.
  • Sie können die Teilnahme jederzeit beenden.

Wer könnte berechtigt sein?

To be able to join this study, you would need to be an adult (18 years or older) with a specific type of ITP called 'primary ITP'. This means your low platelet count isn't caused by another known illness. You should also have shown some improvement in your platelet count with at least one previous ITP treatment, even if that treatment no longer works for you now. Importantly, your ITP should have returned or not responded well to treatments, and your platelet count generally needs to be quite low (under 30,000) on a couple of recent occasions.

There are also some reasons why you might not be able to join. For example, if you've had a blood clot in the past year, or if you recently needed a blood transfusion. People with certain severe heart conditions, a history of blood cancers, or certain types of hepatitis (like Hepatitis B or C) would also not be able to take part. The study team will check your overall health, including your liver and kidney function, to make sure it's safe for you to participate.

Könnte diese Studie für Sie geeignet sein?

Beantworten Sie diese kurzen Fragen, um zu sehen, ob Sie möglicherweise berechtigt sind. Dies ist nur ein Leitfaden – das Forschungsteam trifft die endgültige Entscheidung.

  1. Sind Sie 18 Jahre alt oder älter?
  2. Have you been diagnosed with primary ITP (ITP not caused by another disease)?
  3. Have you tried at least one ITP treatment before, and it helped at some point?
  4. Is your ITP not responding well to current treatments or has it returned?
  5. Are your platelet counts generally below 30,000?
  6. Do you have suitable liver, kidney, and blood cell function (as determined by tests)?
Beantworten Sie jede Frage, um Ihr Ergebnis zu sehen.

Was beinhaltet die Teilnahme?

If you decide to take part in this study, you will be taking the study medicine, pirtobrutinib, as a tablet by mouth. You will have regular visits to the clinic for medical check-ups, which will include physical exams and several blood tests. These blood tests help the study team monitor your platelet counts, check for any side effects, and see how your body handles the medicine. For women who can get pregnant, there will be rules about using contraception during the study. The total time you would be involved in the study could be up to around 16 weeks for the first part or up to 28 weeks for the second part, plus an initial assessment period.

Potenzielle Risiken und Vorteile

Taking part in a clinical trial may offer potential benefits, such as access to a new treatment before it's widely available, and you would receive very close medical attention from the study team. However, there are also potential risks, including side effects from the study medicine, which the researchers will carefully monitor. The study will also involve regular clinic visits and blood tests, which can be time-consuming. You are free to withdraw from the study at any time, for any reason, without it affecting your usual medical care.

Standorte (43)

  • USC Norris Comprehensive Cancer Center
    Verifizierte Postleitzahl
    Los Angeles, Vereinigte Staaten· Rekrutierung
  • Stanford University
    Verifizierte Postleitzahl
    Palo Alto, Vereinigte Staaten· Rekrutierung
  • MedStar Georgetown University Hospital
    Verifizierte Postleitzahl
    Washington D.C., Vereinigte Staaten· Rekrutierung
  • University of Miami Hospital and Clinics Sylvester Comprehensive Cancer Center
    Verifizierte Postleitzahl
    Miami, Vereinigte Staaten· Noch nicht rekrutiert
  • Bleeding and Clotting Disorders Institute
    Verifizierte Postleitzahl
    Peoria, United States· Noch nicht rekrutiert
  • Ochsner Clinic Foundation
    Verifizierte Postleitzahl
    New Orleans, Vereinigte Staaten· Rekrutierung
  • Mayo Clinic
    Verifizierte Postleitzahl
    Rochester, Vereinigte Staaten· Rekrutierung
  • Texas Oncology - Central South
    Verifizierte Postleitzahl
    Austin, Vereinigte Staaten· Rekrutierung
  • MD Anderson Krebszentrum
    Verifizierte Postleitzahl
    Houston, Vereinigte Staaten· Rekrutierung
  • Texas Oncology Gulf Coast
    Verifizierte Postleitzahl
    The Woodlands, United States· Rekrutierung
  • Nanfang Hospital of Southern Medical University
    Verifizierte Postleitzahl
    Guangzhou, China· Rekrutierung
  • Qilu Hospital of Shandong University
    Verifizierte Postleitzahl
    Jinan, China· Rekrutierung

Häufige Fragen

What is ITP?

ITP stands for Immune Thrombocytopenia. It's a condition where your body's immune system accidentally attacks and destroys your own platelets, which are blood cells that help stop bleeding.

What is pirtobrutinib?

Pirtobrutinib is the new medicine being tested in this study. It's designed to help manage ITP.

What is a 'dummy pill' (placebo)?

A dummy pill, or placebo, looks just like the real medicine but contains no active drug. It helps researchers compare the effects of the actual medicine fairly.

Wie lange wird die Studie dauern, wenn ich teilnehme?

The study could last up to about 16 weeks for the first part or up to 28 weeks for the second part, depending on which stage you are in, plus an initial screening period.

Kann ich die Teilnahme an der Studie beenden, wenn ich meine Meinung ändere?

Yes, you can leave the study at any time, for any reason. Your decision will not affect your medical care.

Wie Sie mehr erfahren können

Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or

Sprechen Sie immer mit Ihrem Hausarzt oder Spezialisten, bevor Sie sich entscheiden, an einer Studie teilzunehmen.

Interessiert daran, teilzunehmen?

Registrieren Sie Ihr Interesse

Teilen Sie Ihre Details und das Forschungsteam für "A Study of Pirtobrutinib in Participants With Immune Thrombo… wird Sie kontaktieren, wenn Sie möglicherweise infrage kommen. Sprechen Sie immer mit Ihrem Hausarzt, bevor Sie zustimmen, teilzunehmen.

Diskussion

Community-Diskussion

Bereitgestellt von unserem Forum bei community.patient.info. Bitte seien Sie respektvoll — dies ist kein medizinischer Rat.